Risk factors for imminent fractures: a substudy of the FRISBEE cohort.
Clinical risk factors
Imminent fracture
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
13
10
2020
accepted:
01
12
2020
pubmed:
8
1
2021
medline:
20
5
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
Multiple factors increase the risk of an imminent fracture, including a recent fracture, older age, osteoporosis, comorbidities, and the fracture site. These findings could be a first step in the development of a model to predict an imminent fracture and select patients most at need of immediate treatment. The risk of a recurrent fragility fracture is maximal during the first 2 years following an incident fracture. In this prospective cohort study, we looked at the incidence of recurrent fractures within 2 years after a first incident fracture and we assessed independent clinical risk factors (CRFs) increasing this imminent fracture risk. A total of 3560 postmenopausal women recruited from 2007 to 2013 were surveyed yearly for the occurrence of fragility fractures. We identified patients who sustained a fracture during the first 2 years following a first incident fragility fracture. We quantified the risk of a new fracture and assessed independent CRFs, associated with an imminent fracture at various sites. A recent fracture was a significant CRF for an imminent fracture (OR (95% CI): 3.7 (2.4-5.7) [p < 0.0001]). The incidence of an imminent fracture was higher in subjects above 80 years (p < 0.001). Other CRFs highly predictive in a multivariate analysis were osteoporosis diagnosis (p < 0.01), a central fracture as the index fracture (p < 0.01), and the presence of comorbidities (p < 0.05), with likelihood ratios of 1.9, 1.9, and 2.2, respectively. An imminent fracture was better predicted by a central fracture (p < 0.01) than by a major osteoporotic fracture. The hazard ratio was the highest for a central fracture. In patients with a recent fracture, older age, osteoporosis, comorbidities, and fracture site were associated with an imminent fracture risk. These findings could be a first step in the development of a model to predict an imminent fracture and select patients most at need of immediate and most appropriate treatment.
Identifiants
pubmed: 33411010
doi: 10.1007/s00198-020-05772-8
pii: 10.1007/s00198-020-05772-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1093-1101Références
Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28:1765–1769
pubmed: 28236126
Banefelt J, Åkesson KE, Spångéus A, Ljunggren O, Karlsson L, Ström O, Ortsäter G, Libanati C, Toth E (2019) Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int 30:601–609
pubmed: 30680431
pmcid: 6422949
Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L et al (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187–196
pubmed: 32043227
Eastell R, Rosen CJ, Black DM, Cheung AM (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104:1595–1622
pubmed: 30907953
McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480–1486
pubmed: 22431426
Liu Z, Li CW, Mao YF, Liu K, Liang BC, Wu LG, Shi XL (2019) Study on zoledronic acid reducing acute bone loss and fracture rates in elderly postoperative patients with intertrochanteric fractures. Orthop Surg 11(3):380–385
pubmed: 31058448
pmcid: 6595103
Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30(5):934–944
pubmed: 25545380
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240
pubmed: 29129436
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017a) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427
pubmed: 28892457
Kanis JA, Johansson H, Oden A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757
pubmed: 29947869
pmcid: 6076437
Weycker D, Edelsberg J, Barron R, Atwood M, Oster G, Crittenden DB, Grauer A (2017) Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures. Osteoporos Int 28:2565–2571
pubmed: 28593447
pmcid: 5550536
Johnell O, Kanis JA, Oden A et al (2004a) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179
pubmed: 14691617
Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JEB, Harsløf T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos Int 26:513–519
pubmed: 25187120
Kanis JA, Johnell O, De Laet C et al (2004) A metaanalysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382
pubmed: 15268886
Iconaru L, Moreau M, Kinnard V, Baleanu F, Paesmans M, Karmali R, Body JJ, Bergmann P (2019) Does the prediction accuracy of osteoporotic fractures by BMD and clinical risk factors vary with fracture site? JBMR Plus 3(12):e10238
pubmed: 31844826
pmcid: 6894722
Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780
pubmed: 28028554
Pinedo-Villanueva R, Charokopou M, Toth E, Donnelly K, Cooper C, Prieto-Alhambra D, Libanati C, Javaid MK (2019) Imminent fracture risk assessments in the United Kingdom FLS setting: Implications and challenges. Arch Osteoporos 14(1):12
pubmed: 30712158
pmcid: 6398567
Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11(1):26
pubmed: 27475642
pmcid: 4967418
Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2020b) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 31(10):1817–1828
pubmed: 32613411
pmcid: 7116089
Borgen TT, Bjørnerem A, Solberg LB, Andreasen C, Brunborg C, Stenbro MB, Hübschle LM, Froholdt A, Figved W, Apalset EM, Gjertsen JE, Basso T, Lund I, Hansen AK, Stutzer JM, Omsland TK, Nordsletten L, Frihagen F, Eriksen EF (2019) Post-fracture risk assessment: target the centrally sited fractures first! A substudy of NoFRACT. J Bone Miner Res 34(11):2036–2044
pubmed: 31310352
Kinnard V, Baleanu F, Iconaru L, Moreau M, Paesmans M, Body JJ, Bergmann P (2020) Postfracture risk assessment: target the centrally sited fractures first! A substudy of NoFRACT. J Bone Miner Res 35(4):827–828
pubmed: 32027756
Cappelle SI, Ramon I, Dekelver C, Rozenberg S, Baleanu F, Karmali R, Rubinstein M, Tondeur M, Moreau M, Paesmans M, Bergmann P, Body JJ (2017) Distribution of clinical risk factors for fracture in a Brussels cohort of postmenopausal women: the FRISBEE study and comparison with other major cohort studies. Maturitas 106:1–7
pubmed: 29150162
Baleanu F, Moreau M, Kinnard V, Iconaru L, Karmali R et al (2020a) What is the validity of self-reported fractures? Bone Rep 1(12):100256
Baleanu F, Moreau M, Kinnard V, Iconaru L, Karmali R, Rozenberg S, Rubinstein M, Paesmans M, Bergmann P, Body JJ (2020b) Underevaluation of fractures by self-report: an analysis from the FRISBEE cohort. Arch Osteoporos 15(1):61
pubmed: 32323006
Armitage P, Berry G (1994) Statistical methods in medical research, 3rd edn. Blackwell Scientific Publications, Oxford
Toth E, Banefelt J, Åkesson K, Spångeus A, Ortsäter G, Libanati C (2020) History of previous fracture and imminent fracture risk in Swedish women aged 55 to 90 years presenting with a fragility fracture. J Bone Miner Res 35(5):861–868
pubmed: 31914206
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY (2020a) Algorithm for the management of patients at low/middle/high risk of osteoporotic fracture: a global perspective. Osteoporos Int 31:1–12
pubmed: 31720707
Crandall CJ, Hovey KM, Cauley JA, Andrews CA, Curtis JR, Wactawski-Wende J, Wright NC, Li W, LeBoff MS (2015) Wrist fracture and risk of subsequent fracture: findings from the Women’s Health Initiative Study. J Bone Miner Res 30(11):2086–2095
pubmed: 25990562
Chen W, Simpson JM, March LM, Blyth FM, Bliuc D, Tran T, Nguyen TV, Eisman JA, Center JR (2018) Co-morbidities only account for a small proportion of excess mortality after fracture: a record linkage study of individual fracture types. J Bone Miner Res 33(5):795–802
pubmed: 29314242
Johnell O, Kanis JA, Oden A et al (2004b) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42
pubmed: 14593451
Shauver MJ, Zhong L, Chung KC (2015) Mortality after distal radial fractures in the Medicare population. J Hand Surg Eur 40(8):805–811
Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136
pubmed: 24113837
pmcid: 3880487
Iconaru L, Smeys C, Baleanu F, Kinnard V, Moreau M, Cappelle S, Surquin M, Rubinstein M, Rozenberg S, Paesmans M, Karmali R, Bergmann P, Body JJ (2020) Osteoporosis treatment gap in a prospective cohort of volunteer women. Osteoporos Int 31(7):1377–1382
pubmed: 32128600
Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437–1443
pubmed: 7477143
Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241–1249
pubmed: 15231010
Harris ST, Watts NB, Genant HK, McKeever C, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352
pubmed: 10527181
Cummings SR, San Martin J et al (2007) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007a) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
pubmed: 17476007
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007b) HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822
pubmed: 17476007
Miller PD, Hattersley G, Riis BJ et al (2017) ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543
pubmed: 27641143
Body JJ, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P (2020) Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int 31:1935–1942
pubmed: 32474650
pmcid: 7497508